Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
Acute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged >65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies. The hypothesis of harnessing the immune system against cancer, i...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/10/7/211 |
| _version_ | 1797716300500303872 |
|---|---|
| author | Alessandro Isidori Federica Loscocco Marilena Ciciarello Giulia Corradi Mariangela Lecciso Darina Ocadlikova Sarah Parisi Valentina Salvestrini Sergio Amadori Giuseppe Visani Antonio Curti |
| author_facet | Alessandro Isidori Federica Loscocco Marilena Ciciarello Giulia Corradi Mariangela Lecciso Darina Ocadlikova Sarah Parisi Valentina Salvestrini Sergio Amadori Giuseppe Visani Antonio Curti |
| author_sort | Alessandro Isidori |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged >65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies. The hypothesis of harnessing the immune system against cancer, including leukemia, has been postulated for a long time, and several clinical attempts have been made in this field. In the last years, we increased our knowledge about the interplay between AML and immune cells, but no major improvement has been translated, up to now, from bench to bedside. However, the outstanding results coming from the modern immuno-oncology trials with new drugs have granted a new interest for immunotherapy in AML. Accordingly, the elderly population represents an ideal target, given the low percentage of patients eligible for allogeneic stem cell transplant. With that in mind, in the era of immunotherapy, we consider immunosenescence as the optimal background to start investigating a biology-driven approach to AML therapy in the elderly. By taking into account the physiological age-related changes of immune response, more personalized and tailored use of the new drugs and strategies harnessing the immune system against AML, has the potential to increase their efficacy and impact on clinical outcomes. |
| first_indexed | 2024-03-12T08:19:29Z |
| format | Article |
| id | doaj.art-1fcc67192b2046958fc2c08cd4992d15 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T08:19:29Z |
| publishDate | 2018-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-1fcc67192b2046958fc2c08cd4992d152023-09-02T18:34:01ZengMDPI AGCancers2072-66942018-06-0110721110.3390/cancers10070211cancers10070211Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven ApproachAlessandro Isidori0Federica Loscocco1Marilena Ciciarello2Giulia Corradi3Mariangela Lecciso4Darina Ocadlikova5Sarah Parisi6Valentina Salvestrini7Sergio Amadori8Giuseppe Visani9Antonio Curti10Haematology and Stem Cell Transplant Center, AORMN Marche Nord Hospital, Via Lombroso, 61100 Pesaro, ItalyHaematology and Stem Cell Transplant Center, AORMN Marche Nord Hospital, Via Lombroso, 61100 Pesaro, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seràgnoli”, University of Bologna, Via Massarenti, 9, 40138 Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seràgnoli”, University of Bologna, Via Massarenti, 9, 40138 Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seràgnoli”, University of Bologna, Via Massarenti, 9, 40138 Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seràgnoli”, University of Bologna, Via Massarenti, 9, 40138 Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seràgnoli”, University of Bologna, Via Massarenti, 9, 40138 Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seràgnoli”, University of Bologna, Via Massarenti, 9, 40138 Bologna, ItalyGIMEMA Foundation, 00187 Rome, ItalyHaematology and Stem Cell Transplant Center, AORMN Marche Nord Hospital, Via Lombroso, 61100 Pesaro, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seràgnoli”, University of Bologna, Via Massarenti, 9, 40138 Bologna, ItalyAcute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged >65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies. The hypothesis of harnessing the immune system against cancer, including leukemia, has been postulated for a long time, and several clinical attempts have been made in this field. In the last years, we increased our knowledge about the interplay between AML and immune cells, but no major improvement has been translated, up to now, from bench to bedside. However, the outstanding results coming from the modern immuno-oncology trials with new drugs have granted a new interest for immunotherapy in AML. Accordingly, the elderly population represents an ideal target, given the low percentage of patients eligible for allogeneic stem cell transplant. With that in mind, in the era of immunotherapy, we consider immunosenescence as the optimal background to start investigating a biology-driven approach to AML therapy in the elderly. By taking into account the physiological age-related changes of immune response, more personalized and tailored use of the new drugs and strategies harnessing the immune system against AML, has the potential to increase their efficacy and impact on clinical outcomes.http://www.mdpi.com/2072-6694/10/7/211acute myeloid leukemiatumor immunityimmunotherapyimmunosenescencenew drugscell therapy |
| spellingShingle | Alessandro Isidori Federica Loscocco Marilena Ciciarello Giulia Corradi Mariangela Lecciso Darina Ocadlikova Sarah Parisi Valentina Salvestrini Sergio Amadori Giuseppe Visani Antonio Curti Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach Cancers acute myeloid leukemia tumor immunity immunotherapy immunosenescence new drugs cell therapy |
| title | Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach |
| title_full | Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach |
| title_fullStr | Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach |
| title_full_unstemmed | Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach |
| title_short | Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach |
| title_sort | immunosenescence and immunotherapy in elderly acute myeloid leukemia patients time for a biology driven approach |
| topic | acute myeloid leukemia tumor immunity immunotherapy immunosenescence new drugs cell therapy |
| url | http://www.mdpi.com/2072-6694/10/7/211 |
| work_keys_str_mv | AT alessandroisidori immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT federicaloscocco immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT marilenaciciarello immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT giuliacorradi immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT mariangelalecciso immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT darinaocadlikova immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT sarahparisi immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT valentinasalvestrini immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT sergioamadori immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT giuseppevisani immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach AT antoniocurti immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach |